Umeclidinium is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). It is available as inhalation powder for oral use. MedsAcross supplies Umeclidinium for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Umeclidinium ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Umeclidinium ELLIPTA is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Source: US FDA prescribing information
Umeclidinium is a long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptors at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo studies, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours. The clinical relevance of these findings is unknown. The bronchodilation following inhalation of umeclidinium is predominantly a site-specific effect.
Source: US FDA prescribing information
The recommended dosage of Umeclidinium ELLIPTA for maintenance treatment of COPD is 1 actuation (umeclidinium 62.5 mcg) once daily by oral inhalation. • Umeclidinium ELLIPTA should be used at the same time every day. Do not use Umeclidinium ELLIPTA more than 1 time every 24 hours. • No dosage adjustment is required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment. • For oral inhalation only. • Maintenance treatment of COPD: 1 actuation of Umeclidinium ELLIPTA once daily administered by oral inhalation.
Source: US FDA prescribing information
Umeclidinium ELLIPTA is contraindicated in the following conditions: • Severe hypersensitivity to milk proteins • Hypersensitivity to umeclidinium or any of the excipients • Severe hypersensitivity to milk proteins. • Hypersensitivity to any ingredient.
Source: US FDA prescribing information
• Do not initiate in acutely deteriorating COPD. Do not use to treat acute symptoms. • If paradoxical bronchospasm occurs, discontinue Umeclidinium ELLIPTA and institute alternative therapy. • Worsening of narrow-angle glaucoma may occur. Use with caution in patients with narrow-angle glaucoma and instruct patients to contact a healthcare provider immediately if symptoms occur. • Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.
Source: US FDA prescribing information
The following adverse reactions are described in greater detail in other sections: • Paradoxical bronchospasm • Worsening of narrow-angle glaucoma • Worsening of urinary retention Most common adverse reactions (incidence ≥2% and more common than placebo) include nasopharyngitis, upper respiratory tract infection, cough, arthralgia.
Source: US FDA prescribing information
Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of Umeclidinium ELLIPTA with other anticholinergic-containing drugs.
Source: US FDA prescribing information
Store at room temperature between 68°F and 77°F (20°C and 25°C), excursions permitted from 59°F to 86°F (15°C to 30°C). Store in a dry place away from direct heat or sunlight. Umeclidinium ELLIPTA should be stored inside the unopened moisture-protective foil tray and only removed from the tray immediately before initial use.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Umeclidinium, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Incruse Ellipta 62.5 mcg inhalation powderOral | GlaxoSmithKline | US FDA | Available on request |
| Umeclidinium Ellipta 62.5 mcg inhalation powderOral | Prasco Laboratories | US FDA | Available on request |
2 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 2 presentations of Umeclidinium and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Umeclidinium, including Incruse Ellipta, Umeclidinium Ellipta.
Yes. The US FDA first approved Umeclidinium on 30 April 2014, according to Drugs@FDA.
Yes. Umeclidinium has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Umeclidinium is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Umeclidinium is classified under ATC code R03BB07 (Umeclidinium).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.